RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a ...

Inside the Booming mRNA Therapeutics MarketThe mRNA Cancer Vaccines and Therapeutics Market has emerged as one of the most ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Messenger RNA (mRNA) therapeutics hold significant promise for the future of personalized cancer treatment, but persistent off-target effects and treatment-resistant tumor microenvironments have ...

The 9 therapeutics stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 5.7%. In ...